Aomeier's 'Ageng' Wins NMPA Approval, Challenging Originator Sugammadex in China
A Chinese biotech company has secured approval for the country's first domestically developed neuromuscular blocking agent reversal drug, marking a milestone in Beijing's push to build indigenous pharmaceutical capabilities in specialized hospital medicines.
Hangzhou Aomeier Pharmaceutical, a biotech firm with more than two decades of research history, announced June 30 that China's National Medical Products Administration approved its Class 1 innovative drug, Ageng Sodium Injection, marketed under the brand name Aomeikesong. The approval, publicly disclosed July 1, positions Aomeikesong as the first Chinese-developed targeted antagonist for neuromuscular blockade reversal—a critical post-surgical intervention that helps patients recover breathing function after general anesthesia.
The drug is being produced by Zhejiang Xianju Pharmaceutical Co., Ltd., one of China's leading generic and specialty drug manufacturers, while domestic marketing and promotion rights have been assigned to Aishijian, a commercialization partner.
Clinical Performance and Safety Profile
Aomeikesong received multiple rounds of funding under China's National Major New Drug Creation Program, a government initiative designed to accelerate development of innovative pharmaceuticals. The drug works by reversing the effects of rocuronium, a commonly used neuromuscular blocking agent during surgery.
According to clinical trial data, Aomeikesong demonstrated rapid reversal capabilities in two Phase III head-to-head studies. The drug achieved median recovery times of 2.25 minutes for moderate neuromuscular blockade and 2.48 minutes for deep blockade—both within a three-minute window. The molecular structure was modified from a cyclodextrin scaffold to reduce allergic reactions, a known side effect of similar drugs.
The company reported that Aomeikesong showed a significantly lower rate of re-curarization—a condition where muscle weakness returns after initial recovery—compared with the reference drug. Throughout the trials, no significant allergic or cardiovascular adverse reactions were observed.
Market Opportunity and Competitive Landscape
The approval places Aomeikesong in direct competition with Sugammadex Sodium, a blockbuster drug developed by MSD known as Sugammadex internationally. Sugammadex generated more than 1.8 billion yuan (approximately $250 million) in global sales in 2025, with China's terminal market size approaching 1 billion yuan (approximately $140 million).
While more than 20 Chinese companies have received approval for generic versions of sugammadex, Aomeikesong holds a distinct advantage: it remains the only neuromuscular antagonist globally with complete patent protection still in force. This patent position, combined with its differentiated safety profile, could provide Aomeier with pricing power and market exclusivity in a segment increasingly crowded with generics.
The competitive landscape is evolving. Hengrui Medicine, one of China's largest pharmaceutical companies, has its own next-generation neuromuscular antagonist, HRS-2162, currently in Phase I clinical trials in China. The emergence of domestic competitors signals the beginning of a more contested market for advanced reversal agents.
Global Expansion Strategy
Aomeier is pursuing an international development pathway for Aomeikesong. The company has completed an ethnic bridging study in Australia, a regulatory requirement for demonstrating the drug's efficacy across different populations. In the United States, Aomeier has concluded an End-of-Phase II meeting with the Food and Drug Administration, a key milestone in the drug development process.
The company plans to launch a global multi-center clinical trial within this year, expanding the drug's clinical data package across multiple international sites. Aomeier is also advancing several other pipeline candidates in anesthesia and cardiovascular indications through overseas clinical programs, signaling a broader ambition to establish itself as a global specialty pharmaceutical player.
The three-way commercialization structure—Aomeier as the marketing authorization holder, Xianju Pharmaceutical as the exclusive manufacturer of both active pharmaceutical ingredients and finished formulations, and Aishijian handling all domestic marketing—reflects a common model in China's biotech industry, where smaller innovators partner with established manufacturers and commercial specialists to bring new drugs to market.
Note: All financial figures cited in this article are denominated in Chinese yuan (RMB/CNY). Exchange rates are approximate and based on current market conditions.